Cyndeo Wealth Partners LLC Takes Position in Heron Therapeutics, Inc. $HRTX

Cyndeo Wealth Partners LLC purchased a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) during the second quarter, according to its most recent filing with the SEC. The firm purchased 248,087 shares of the biotechnology company’s stock, valued at approximately $514,000. Cyndeo Wealth Partners LLC owned 0.16% of Heron Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. RFP Financial Group LLC purchased a new position in shares of Heron Therapeutics in the 1st quarter valued at $26,000. Valeo Financial Advisors LLC boosted its position in shares of Heron Therapeutics by 34.1% in the 1st quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 4,619 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of Heron Therapeutics by 168.8% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 27,867 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 17,500 shares in the last quarter. Wealth Alliance LLC acquired a new stake in shares of Heron Therapeutics in the 1st quarter worth $70,000. Finally, Deutsche Bank AG boosted its position in shares of Heron Therapeutics by 43.2% in the 1st quarter. Deutsche Bank AG now owns 85,610 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 25,824 shares in the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on HRTX shares. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 7th. Wall Street Zen cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Wednesday. Finally, Needham & Company LLC lowered their price objective on Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $1.28 on Friday. The business’s 50-day simple moving average is $1.34 and its two-hundred day simple moving average is $1.79. The company has a market cap of $234.64 million, a PE ratio of -64.00 and a beta of 1.25. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $2.68.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Friday, August 8th. The biotechnology company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.01). The business had revenue of $37.20 million during the quarter, compared to analyst estimates of $38.08 million. Heron Therapeutics has set its FY 2025 guidance at EPS. As a group, analysts predict that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Insider Activity

In related news, Director Adam Morgan acquired 1,766,546 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $1.50 per share, with a total value of $2,649,819.00. Following the acquisition, the director directly owned 8,753,290 shares in the company, valued at $13,129,935. This represents a 25.28% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Rubric Capital Management Lp acquired 2,387,225 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $1.50 per share, with a total value of $3,580,837.50. Following the acquisition, the insider owned 29,100,728 shares in the company, valued at approximately $43,651,092. This trade represents a 8.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 5.86% of the company’s stock.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.